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Background: Recent work led to recognize sessile serrated adenomas (SSA) as precursor to many of the sporadic
colorectal cancers with microsatellite instability (MSI). However, comprehensive analyses of DNA methylation in SSA
and MSI cancer have not been conducted.
Methods: With an array-based methylation sensitive amplified fragment length polymorphism (MS-AFLP) method
we analyzed 8 tubular (TA) and 19 serrated (SSA) adenomas, and 14 carcinomas with (MSI) and 12 without (MSS)
microsatellite instability. MS-AFLP array can survey relative differences in methylation between normal and tumor
tissues of 9,654 DNA fragments containing all NotI sequences in the human genome.
Results: Unsupervised clustering analysis of the genome-wide hypermethylation alterations revealed no major differences
between or within these groups of benign and malignant tumors regardless of their location in intergenic, intragenic,
promoter, or 3′ end regions. Hypomethylation was less frequent in SSAs compared with MSI or MSS carcinomas. Analysis
of variance of DNA methylation between these four subgroups identified 56 probes differentially altered. The hierarchical
tree of this subset of probes revealed two distinct clusters: Group 1, mostly composed by TAs and MSS cancers with KRAS
mutations; and Group 2 with BRAF mutations, which consisted of cancers with MSI and MLH1 methylation (Group 2A),
and SSAs without MLH1 methylation (Group 2B). AXIN2, which cooperates with APC and β-catenin in Wnt signaling, had
more methylation alterations in Group 2, and its expression levels negatively correlated with methylation determined by
bisulfite sequencing. Within group 2B, low and high AXIN2 expression levels correlated significantly with differences in size
(P = 0.01) location (P = 0.05) and crypt architecture (P = 0.01).
Conclusions: Somatic methylation alterations of AXIN2, associated with changes in its expression, stratify SSAs according
to some clinico-pathological differences. We conclude that hypermethylation of MLH1, when occurs in an adenoma cell
with BRAF oncogenic mutational activation, drives the pathway for MSI cancer by providing the cells with a mutator
phenotype. AXIN2 inactivation may contribute to this tumorigenic pathway either by mutator phenotype driven frameshift
mutations or by epigenetic deregulation contemporary with the unfolding of the mutator phenotype.
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Recent advances in colon cancer research have revealed
a new pathological pathway distinct from the traditional
pathway, the tubular adenoma-carcinoma sequence [1].
This alternative pathway has been recognized as the ser-
rated pathway, in which sessile serrated adenoma (SSA)
replaced the traditional tubular adenoma as the precur-
sor lesion of a subset of colorectal cancer [2].
SSA was identified as a new entity by Torlakovic et al.
in 1996 [3] and later classified in a new category, the ser-
rated polyps [2]. The serrated polyps include hyperplas-
tic polyps, traditional serrated adenomas and sessile
serrated adenomas, the characteristics of which are ser-
rated structure in the crypt epithelium [4-6]. Serrated
polyp nomenclature is evolving and interpretation of the
literature is complicated by differing interpretations of the
morphological features of serrated polyps. Even among ex-
pert gastrointestinal pathologists there is significant inter-
observer variability in classification [7,8].
Regardless of the difficulty in the definition, recent
research efforts led to recognize that serrated polyps,
especially SSA seemed to be precursor to many of the
sporadic colorectal cancers with microsatellite instability
(MSI) [9]. Mismatch repair deficiency leads to the accu-
mulation of hundred of thousands of somatic mutations
in microsatellite sequences [10]. This mutator phenotype
defined a specific molecular pathway for colon cancer
because the mutated cancer genes are in general differ-
ent than those from cancers without MSI [10,11]. SSAs
and MSI cancers were reported to exhibit similar fea-
tures including predominant location in the proximal
colon, high BRAF and low KRAS mutation and enhanced
DNA hypermethylation [12-17].
Somatic hypermethylation of CpG islands in some
genes includes the silencing of the MLH1 mutator gene
and thus underlies many of the MSI sporadic cancers.
Some investigators conferred distinctive phenotypic and
biological properties to the tumors displaying a so-called
CpG island methylator phenotype (CIMP), which was
viewed as preceding the development of a subset of MSI
colon cancers [18,19]. However, no apparent bimodal
distribution was seen for the somatic hypermethylation
alterations in gastrointestinal cancers [20,21] thus challen-
ging the CIMP hypothesis. Nearly 15 years later, the CIMP
concept, despite the publication of many CIMP papers
(reviewed in [22]) still awaits for a clear definition, including
a stable set of CIMP markers, as well as for identification of
the underlying methylator gene(s) [22,23].
Despite of the elusive CIMP entity, the importance of
somatic hypermethylation as responsible for the silencing
of several tumor suppressors and the MLH1 mutator gene,
and as a consequence the resulting MSI mutator pheno-
type, is highlighted by the evidence that SSA display DNA
methylation alterations that are frequently observed in MSIcancer [9,24-26]. However, comprehensive analyses of
methylation alterations in SSA and MSI cancer have not
been conducted.
Methylation sensitive amplified fragment length poly-
morphism (MS-AFLP) is a fingerprinting technique devel-
oped by Yamamoto et al. as a tool to analyze DNA
methylation in hundreds of loci simultaneously [27,28]. The
approach utilized NotI restriction endonuclease for target-
ing methylation changes in any of the two CpG sites within
its recognition sequence GCpGGCCpGC. Because nearly
half of all NotI sites (44%) are located in or adjacent to CpG
islands, while the rest are located outside, MS-AFLP en-
abled to detect both relative DNA hypermethylation and
hypomethylation somatic alterations throughout the gen-
ome. Comparing the intensity of the fingerprint bands
from normal and tumor tissue DNA provided an unbiased
insight of the complex picture of those epigenetic alter-
ations. Employing this technique for the study of colorectal
cancer we demonstrated that the MSI phenotype was dom-
inant over hypermethylation [21] and that some of the
tumors without MSI could be rationalized by an age-
associated accumulation of DNA hypomethylation [23].
More recently, we developed a novel MS-AFLP array-
based platform containing probes consisting of 60-mer-
oligonucleotides, which cover the sequences adjacent to
all the 9645 NotI sites identified in the human genome
[29]. In this study, we performed a comprehensive analysis
of methylation alterations to characterize the epigenetic
profiles of colon adenomas and carcinomas of different




Nineteen patients with sessile serrated adenoma (SSA), 8
with tubular adenoma (TA) and 26 with proximal colon
cancer including 12 and 14 tumors with and without
MSI, respectively were recruited in this study. These
were from the series analyzed in our previous study,
which had enough amount and high quality of DNA and
RNA available for microarray analysis [17]. SSAs, TAs
and colorectal cancer tissues were prospectively collected
in Jichi Medical University Hospital and Jichi Medical
University Saitama Medical Center. SSA and TA were ob-
tained endoscopically and classified with two categories by
the location, i.e., proximal and distal.
SSA was diagnosed by five architectural features; basal
crypt serration, basal dilatation of the crypts, crypts that
run horizontal to the basement membrane, crypt branching
and surface villosity or papillarity as previously described
[17,30-32]. When the endoscopically resected polyp exhib-
ited two or more features was diagnosed as SSA. Lesions
showing typical histological features of so-called “traditional
serrated adenoma” [5] were excluded from the analysis.
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underwent surgical treatment. In all of the lesions, a part
of the tissue was taken in fresh and was frozen immedi-
ately for genetic analysis and the rest of the tissue was
used for histological analysis. Proximal lesions were
defined as proximal to splenic flexure, whereas distal
lesions were defined as distal to splenic flexure. All colo-
rectal cancer tissues were collected from proximal colon.
Written informed consent for participation in the study
was obtained from all participants. This study was ap-
proved by Jichi Medical University Institutional Review
Board.
DNA and RNA extraction
DNA was extracted by DNeasy® blood and tissue kit
(Qiagen, Hilden, germany). Total RNA was extracted
from tissue culture cell lines by TRIzol® Plus RNA purifi-
cation kit (Invitrogen, Carlsbad, CA, USA).
BRAF and KRAS mutation analysis
BRAF (T1799A) and KRAS mutations were determined
by direct sequencing after polymerase chain reaction
(PCR) amplification of exon 15 of the BRAF gene and
codon 12 and 13 of the KRAS gene. For detection of the
BRAF mutation, genomic DNA obtained from fresh
frozen samples was amplified using: forward, 5′-TCAT
AATGCTTGCTCTGATAGGA-3′ and reverse, 5′-GG
CCAAAAATTTAATCAGTGGA-3′ primers. For the
detection of the KRAS mutation, the following primers
were used: forward, 5′-CTGAAAATGACTGAATA
TAAACTTGT-3′ and reverse, 5′-ATATGCATATTA
AAACAAGATTTACC-3′ as described [17,33,34]. PCR
products were purified on a YM-30 Microcon column
(Millipore) and sequenced using the BigDye terminator
v3.1 cycle sequencing kit on ABI Prism 3100 (both
from Applied Biosystems, Tokyo).
MSI analysis
Genomic DNA was extracted from fresh frozen samples
using the EZ1 DNA tissue kit (Qiagen, Tokyo, Japan)
and was amplified by PCR using the monomorphic
markers BAT25 and BAT26 as previously described [27].
PCR products were analyzed by Gene Scan using ABI
Prism 3100, and the sample was scored showing MSI if
there were additional peaks in the PCR products, or
otherwise scored as microsatellite stable (MSS).
MLH1 and CpG island methylation
Combined bisulfite restriction analysis was performed to
assess gene methylation using primers that were de-
signed to amplify the regions around the transcription
start sites of the target genes [35]. Bisulfite modification
was performed using the Epitect Bisulfite kit (Qiagen),
as described previously [36]. Genomic DNA (1 μg) wasused for conversion with the bisulfite reagent. The pri-
mer sequences, annealing temperatures and restriction
enzymes utilized were identical to those previously de-
scribed [37]. After digestion, products were electropho-
resed on 2% agarose gels and stained with ethidium
bromide. Methylation density was confirmed using the
image analysis program Image J, and positive methyla-
tion was defined when the methylation- sensitive restric-
tion enzyme digested ≥10% of the DNA [37].
Preparation, labeling and hybridization of DNA samples
for MS-AFLP arrays
The genome-wide methylation profile was determined
by a high-throughput array-based analysis of methylation
alterations. For this purpose, we introduced an array-
based approach of the methylation sensitive amplified
fragment length polymorphism (MS-AFLP) fingerprint-
ing method, which can survey most of the 9654 DNA
fragments containing all NotI sequences in the genome,
as previously described [27,38]. Genomic DNA was iso-
lated by QIAamp DNA Mini Kit (QIAGEN, Hilden,
Germany). The initial steps of the MS-AFLP were per-
formed as previously described [27,38]. Briefly, 1 μg of
genomic DNA was digested overnight with 5 units of
methylation-sensitive NotI (Promega, Madison, WI, USA)
and 2 units of methylation-insensitive Mse I (NE Biolabs,
Beverly, MA, USA) at 37°C. Two pairs of oligonucleo-
tides were annealed overnight at 37°C to generate NotI
(5′-CTCGTAGACTGCGTAGG-3′ and 5′-GGCCCCT
ACGCAGTCTAC-3′) and Mse I (5′-GACGATGAG
TCCTGAG-3′ and 5′-TACTCAGGACTCAT-3′) spe-
cific adaptors.
The digested DNA was ligated in 1.25 μl each of 5
pmol/μl NotI and 50 pmol/μl Mse I adaptor using 1 unit
of T4 DNA ligase (Promega) overnight at 16°C. The
adaptor-ligated template DNA was amplified by PCR
using NotI (5′-GACTGCGTAGGGGCCGCG-3′) and
Mse I (5′-GATGAGTCCTGAGTAA-3′) primers. The
PCR mixture consisted of 6 ng of NotI primer, 30 ng of
Mse I primer, 0.25 mM dNTP, and 1.5 unit of AmpliTaq
DNA polymerase (Applied Biosystems, Foster City,
California, USA) in a final volume of 20 μl. The PCR
started at 72°C for 30 s and 94°C for 30 s, followed by
35 cycles of 94°C for 30 s, 52°C for 30 s, and 72°C for
2 min. The final extension was performed for 10 min at
72°C. The reactions were then kept at 10°C until the
amplified DNA fragments were isolated using a QIA
PCR Clean-up kit (Qiagen). DNA was eluted into 50 μl
of elution buffer.
Prior to hybridization on the MS-AFLP arrays, the
DNA samples were differentially labeled as previously
described [27,38]. Briefly, fluorescently labeled fragments
were prepared using the Bioprime labeling system (Invi-
trogen). Each sample of PCR-amplified DNA (50 ng/
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Primer Mix solution. The mixtures were boiled at 100°C
for 2 min, quickly placed on ice for 1 min, and briefly
centrifuged for 10 s. Then 1 μl of either CY5 Mix solu-
tion (1.56 mM each of dGTP, dATP and dTTP, 0.22 mM
dCTP, and 0.11 mM Fluorolink CY5-dCTP) or CY3 Mix
solution (1.56 mM each of dGTP, dATP, and dTTP,
0.22 mM dCTP, and 0.11 mM Fluorolink CY3-dCTP)
was added. Fluorolink CY5-dCTP and CY3-dCTP were
purchased from Amersham-Pharmacia. Klenow frag-
ment of E. coli DNA polymerase was then added to a
final concentration of 0.8 U per μl. The mixtures were
incubated at 37°C for 1 h before adding 2 μl of stop so-
lution (0.5 M EDTA) to terminate the reaction.
The CY5 and CY3 fluorescently labeled DNA fragments
were separated from the unincorporated dNTPs by fil-
tration through Microcon YM-30 columns (Millipore,
Bedford, MA, USA). Each sample was reconstituted
with 1× TE (pH 8.0) to a final volume of 37 μl, and
2 μl of each sample was taken to determine the yield of
labeled genomic DNA and the specific activity after la-
beling and clean-up. Exposure of samples to light was
minimized during all experimental procedures.
The Cy3 and Cy5 labeled DNA samples were mixed in
a siliconized tube with 70 μl of Agilent 2× Hi-RPM Buf-
fer (Agilent, Santa Clara, CA, USA). The mix was heated
at 95°C for 3 min and centrifuged at 6000 × g for 1 min
to collect the sample at the bottom of the tube. One
hundred and ten μl of hybridization sample mixture was
applied slowly to the gasket slide into the Agilent
SureHyb chamber base. Then, one microarray slide was
placed onto the gasket slide, with the active side facing
down. The SureHyb chamber was covered onto the
slides, and the clamp assembly was slid onto both pieces.
The assembled slide chamber was placed in a rotator rack
inside a hybridization oven and rotated at 20 rpm and hy-
bridized at 65°C for 40 hours. After hybridization, array
slides were washed with Oligo aCGH Wash Buffer 1 at
room temperature for 5 minutes and Oligo aCGH Wash
Buffer 2 at 37°C for 1 min. To prevent Cy5 degradation by
ozone, the slides were washed with acetonitrile for 30 sec-
onds and then with Stabilization and Drying Solution for
30 seconds. The arrays were scanned using an Agilent
G2565BA DNA Microarray Scanner.
Quantitative reverse transcription-PCR
Tissue specimens were immediately added to RNA later
(Ambion, Austin, TX, USA) and stored at -80°C until
DNA or RNA extraction. Total RNA was immediately
treated with DNase I (Invitrogen, Carisbad, CA, USA) and
reverse-transcribed using a Superscript II reverse tran-
scriptase kit (Invitrogen) to prepare first-strand cDNA.
The primer sequences for AXIN2 were 5′-CTGGCTCCA
GAAGATCACAAAG-3′ (forward) and 5′-ATCTCCTCAAACACCGCTCCA-3′ (reverse). Thermal cycling con-
ditions were 42°C for 60 min (cDNA synthesis), 95°C for
30 sec (hot start), and then 40 cycles of 95°C for 5 sec,
60°C for 30 sec, and 72°C for 60 sec. The expression level
of AXIN2 was determined using the fluorescence intensity
measurements from the ABI 7900HT Real-Time PCR Sys-
tem Data Analysis Software. An ACTB fragment was amp-
lified as an internal control.
Bisulfite sequencing analysis
DNA sequencing was performed after bisulfite modifica-
tion, as previously described [36]. The primers for the
bisulfite sequencing were 5′-TTGTATATAGTTTAGYG
GTTGGG-3′ (forward) and 5′-AAATCTAAACTCCC
TACACACTT -3′ (reverse). PCR was performed for
45 cycles, consisting of denaturation at 95°C for 30 sec,
annealing at 58°C for 30 sec, and extension at 72°C for
60 sec, followed by a final 7-min extension at 72°C for all
primer sets. The sequences were subjected to a BLAST
search to determine their location in the genome.
Statistics
Fisher’s exact was used to examine associations between
two categorical variables. Continuous variable compari-
sons between two groups were performed with the
Student’s t-test for those variables following a normal
distribution, or with the non-parametric Mann–Whit-
ney-Wilcoxon test for those variables that do not follow
a normal distribution. The level of statistical significance
was set at P < 0.05, unless otherwise specified. To deter-
mine the significant genes from multiple samples, vari-
ance of analysis (ANOVA) with Bonferroni correction
was carried out using MeV [39], by which hierarchical
clustering sample and gene trees were also drawn, simul-
taneously. The threshold of significance was determined
by Bonferroni correction set at P = 0.05. To account for
the bias due to the partial gene representation in the
MS-AFLP Array, all the gene enrichment analyses were
performed using the list of the genes present in the array
as a background, instead of the total number of genes in
the human genome [38].
Results
Clinicopathological and molecular features of samples
The clinicopathological and molecular features of the
four subgroups of tumors, tubular adenomas (TA) sessile
serrated adenomas (SSA), and MSI and MSS carcinomas,
are summarized in Table 1. Patient gender and stage were
not significantly different between each group. Patients with
MSI cancers were older than those with SSA (P = 0.01).
MSI associated with poorly differentiated phenotype. KRAS
mutation was more prevalent in MSSs and TAs as com-
pared to MSIs and SSAs (P < 0.01), whereas BRAF muta-
tion was preferentially observed in MSIs and SSAs as
Table 1 Clinicopathological and molecular data of colon adenomas and carcinomas
TA (n = 8) SSA (n = 19) MSS (n = 12) MSI (n = 13) P-value3
Age 65.4 ± 4.4 60.6 ± 9.8 62.2 ± 8.2 70.8 ± 11.3 0.019(a)
Gender (M/F) 4/4 13/6 6/6 6/7 0.57
Duke’s stage NA NA 7/5 11/2 0.20
(A or B/C)
Grade1 NA NA 12/0 9/4 0.096
(W-M/P)
KRAS Mutations 4/8 0/19 4/12 0/13 0.0011
(mut/total)
BRAF Mutations 0/8 19/19 4/12 9/13 2.2×10−6
(mut/total)
hMLH1 Methylation (+/total ) 0/8 0/19 0/12 5/13 8.6×10−4
Hypermethylation2 1.8 ± 1.4% 1.2 ± 0.6% 1.2 ± 0.6% 1.9 ± 1.2% 0.15(a)
Hypomethylation2 0.6 ± 0.4% 0.3 ± 0.2% 1.0 ± 0.5% 1.0 ± 0.6% 5.8×10−4(a)
1Tumor grade. Well (W), moderately (M) or poorly (P) differentiated.
2Hypermethylation and hypomethylation indicate the percentage of MS-AFLP array probes with values surpassing the hypermethylation and hypomethylation
thresholds, respectively.
3For categorical data, p-values were calculated by χ2 test when comparing four groups, or by Fisher’s exact test when comparing two groups. For continuous data,
we applied one-way ANOVA followed by Tukey’s HSD multi-hypothesis testing correction. The most Statistically significant p-value after correction corresponded
always to the SSA vs MSI comparison(a). In hypomethylation, a significant difference between SSA and MSS was also found (P = 0.0014). P-values below 0.05 are in
bold type.
NA: Not applicable.
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was detected only in MSI carcinomas.
Genome-wide surveillance of methylation alterations
by MS-AFLP revealed no significant differences between
the 4 groups (Table 1). Also, there was no significant dif-
ference in the overall frequency of hypermethylation al-
terations (including intragenic and intergenic regions)
and in the promoter and 3′end regions (Figure 1). There
was a borderline difference in methylation frequency at
intragenic and 3′end regions (P = 0.035 and P = 0.041,
respectively) between SSAs and MSI carcinomas due to
the higher number of alterations of the later (Additional
file 1: Figure S1). Regarding hypomethylation, SSAs
displayed fewer alterations than MSS and MSI carcin-
omas overall and in the different gene regions although
the differences were more pronounced compared with
the MSI carcinomas (Figure 1 and Additional file 1:
Figure S1).
Since the MS-AFLP array covers all NotI sites in the
genome, these results extend our previous findings with
the MS-AFLP DNA fingerprinting lower resolution ap-
proach showing that the original method reflected a
panoramic view of the somatic methylation alterations
undergone by colon cancers at NotI sites.
Differentially methylated loci in TA, SSA, MSS and MSI
To identify the possible existence of distinct methylation
profiles specific for each of the four different tumor
subgroups, unsupervised hierarchical clustering wasperformed using 9,645 probe sets, but the results re-
vealed no clear differences (data not shown). We, then,
carried out an analysis of variance (ANOVA) to deter-
mine whether there were particular loci specifically asso-
ciated with these tumor subgroups, especially with
serrated adenomas. This analysis resulted in the identifi-
cation of 56 distinctive probes, corresponding to 35
genes, 5 putative loci and 12 intergenic sequences
(Figure 2 and Additional file 1: Table S1) that appeared
altered differentially among these subgroups.
The ANOVA-constructed hierarchical tree revealed two
distinct subsets of samples (Groups 1 and 2, Figure 2).
Seven MSSs (58.3%) and 2 MSIs (14.3%) cancers, as well
as 7 TAs (87.5%) were assigned to Group 1, while 12 MSIs
(85.7%), all 19 SSAs (100%), 5 MSSs (41.7%) and 1 TA
(12.5%) to Group 2. Group 1 thus, consisted of many tu-
mors participating in the tubular adenoma-carcinoma
pathway (TAs and MSSs cancers), whereas Group 2 in-
cluded many SSAs and MSI cancers (Figure 2).
Distinct methylation profiles associates with SSAs
including AXIN2
The clustering into two distinct groups by the ANOVA
approach allowed performing t-test analysis of these two
groups (Additional file 1: Figure S2). The constructed
hierarchical tree revealed distinct epigenetic profiles, one
of which was shared by many of the MSI cancers and
SSAs, and another, which was shared by MSS carcin-
omas and TAs. T-test also identified 168 probes that
Figure 1 Frequency of hypermethylation (left) and hypomethylation (right) estimated by MS-AFLP arrays. TA, in light blue: tubular adenomas.
SSA, in dark blue: sessile serrated adenomas. MSS, in yellow: microsatellite stable carcinomas. MSI, in orange: microsatellite instable carcinomas. Frequencies
were calculated as the percentage of probes with log2 ratio value below −1.5 (for hypermethylation) or above 1.5 (for hypomethylation), after filtering
the 30% lower-intensity probes from each array. Top graphs, results including all probes after filtering (13,515 probes per array). Bottom graphs, results
considering only the probes within ±2.5 Kb of the 5′ end of genes (range: 7,924 to 8,035 probes per array). P-values were calculated by one-way ANOVA
followed by Tukey’s HSD multi-hypothesis testing correction. Only p-values below 0.05 are shown.
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pathway and the tubular adenoma-MSS carcinoma path-
way (Additional file 1: Figure S2). AXIN2 was one of
these genes, which displayed a distinct level of methylation
alterations between the two groups (black bar at right
margins of Figure 2 and Additional file 1: Figure S2).
Group 2 was further classified into two subgroups,
one of which included most MSI cancers (71.4%, Group-
2A), and the other which contained all the SSAs (100%,
Group-2B) (Figure 2). Group 1 displayed high frequency
of KRAS mutation whereas Group 2 exhibited high fre-
quency of BRAF mutation (Figure 2 bottom). While
Group 2 harbored many of MSI cancers and all SSAs, as
expected, methylation of MLH1 was only seen in MSI
cancers in Group 2A. Group 2B was also subdivided into
two groups, 2B-1 and 2B-2, according to the hierarchical
tree (Figure 2 bottom).
Expression of AXIN2 associates with methylation
alterations
ANOVA analysis identified AXIN2, which plays an im-
portant role in Wnt signaling pathway cooperating with
APC and b-catenin, being more frequently altered in
Group 2 that included the serrated adenomas. We mea-
sured the abundance of the corresponding AXIN2
mRNA in the original SSAs and MSI cancers (Group 2)by quantitative reverse transcription–polymerase chain re-
action (RT–PCR). The expression levels were variable, with
some tumors showing little or no expression, while others
exhibited a relatively high expression (Figure 3 right).
When the expression levels of AXIN2 were compared
between the different groups according to the hierarch-
ical tree (Figure 2), the groups 2A and 2B-1 exhibited
low expression levels of AXIN2, whereas group 2B-2 had
significant higher levels of expression of AXIN2 (Figure 3,
left). To examine whether the decreased levels of AXIN2
mRNA was linked to aberrant methylation, the degree of
methylation alterations of 12 CpG sites within the
AXIN2 promoter region (Figure 3 middle) was assessed
in 5 plasmid clones of each of several samples from
groups 2A, 2B-1 and 2B-2. The AXIN2 promoter ap-
peared more methylated in samples from Group 2A than
in Groups 2B-1 and 2B-2 (Figure 3 middle). Also, a
tumor cell line with high methylation (HCT116) exhib-
ited lower expression of AXIN2 than another cell line
(Caco2) with little methylation (Figure 3, top of middle
and right panels).
Expression of AXIN2 associates with different
clinicopathological features of SSAs
The clinicopathological features of SSAs were analyzed in
regards to the observed differences in AXIN2 methylation
Figure 2 Clustering of the samples according to their methylation profile. Hypermethylation is indicated in red. Hypomethylation is
indicated in blue. Samples are shown on top of the heatmap. In white, the normal tissue DNA mix used as reference. Colors for the four tumor
groups are as in Figure 1. On the right side of the heatmap, the genes associated to MS-AFLP probes. AXIN2 probes are indicated in black.
Clustering was performed by complete linkage using Pearson’s correlation on a subset of MS-AFLP probes previously selected by ANOVA. Group
1 contains mostly tubular adenomas and MSS carcinomas. Group 2A contains the majority of MSI carcinomas, and 5 MSS carcinomas. All the
sessile serrated adenomas are grouped in 2B1 and 2B2. Below the heatmap, in black, cases positive for mutation in BRAF or KRAS, or hypermethylation
of hMLH1.
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results are shown in Table 2. No differences were evident
between these two groups in age, gender, presence of car-
cinoma in the adenoma, or mucinous phenotype. How-
ever, the adenomas with high methylation and low
expression (Group 2B-1) were significantly smaller, were
more distal, and exhibited less crypt branching than those
adenomas with low levels of methylation and high levels
of expression (Group 2B-2).
Discussion
In this study, genome-wide surveillance of hypermethy-
lation alterations in NotI sites by MSFLP-array revealed
that somatic hypomethylation was lower in SSAs com-
pared with MSI or MSS carcinomas. These benign tu-
mors also occurred in younger individuals compared
with MSI carcinomas. This is consistent with theproposed hypothesis of demethylation as a gradual accu-
mulation of methylation replication errors during aging
[23] assuming SSAs being the precursors of the MSI car-
cinomas. In contrast, there were no major differences in
global hypermethylation between these groups of benign
and malignant tumors regardless of their location in
intergenic, intragenic, promoter, or 3′end regions. Un-
supervised clustering analysis revealed no clear differ-
ences in the patterns of hypermethylatuon between or
within the four different tumor groups. Only after apply-
ing an ANOVA approach was possible to discern that
MSS cancers and TAs shared similar epigenetic features,
so did MSI and SSA, as reported previously [12-17]. The
study also disclosed distinct profiles of genes relevant for
colorectal cancer such as homeobox genes, transcription
factors, growth factors and genes in the Wnt signaling
pathway, including AXIN2.
Figure 3 Left: AXIN2 mRNA expression level of samples selected from cluster 2A, 2B1 and 2B2. Expression levels were analyzed by Q-PCR
using ACTB housekeeping gene for normalization. Thick horizontal lines within the boxes indicate the median value. Thin dashed horizontal lines
indicate the mean value. Middle: bisulfite sequencing results of the 0.5Kb upstream region of the first exon of AXIN2. CpG sites are represented by
a white or a black circles for unmethylated or methylated sites, respectively. Right: AXIN2 mRNA expression level in colorectal cancer cell lines
HCT116 (MSI, white bar) and Caco2 (MSS, stripped bar), and tumors, both sessile serrated adenomas (black bars) and MSI carcinomas (white bars),
ordered from lower to higher (top to bottom). Arrows between middle and right panel connect those cases for which both the bisulfite
sequencing and the mRNA expression results are shown in the figure.
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ing activation in SSAs but they are controversial [40-44].
Possible explanations to account for the discrepancies
may include that some SSAs were misdiagnosed and
wrongly categorized due to the complication in the def-
inition of serrated polyps [45]. Therefore, a standardizedTable 2 Comparison of SSAs according to AXIN2 expression s
Group 2B-1 (n = 8)
Gender (Male/Female) 4/4
Patient Age (years) 62.8 ± 9.9
(Range, Median) (46–74, 63)
Tumor Size (mm) 9.4 ± 1.9











1Anatomical location. Cecum (C). Ascending (A). Transversal (T).
2Crypt branching was defined by the appearance of splits or fissures in the base of
3Hypermucinous appearance.
4P-values were calculated by Fisher’s exact test for categorical variables and unpairediagnosis of SSA formulated recently [30,32] was applied
in this study.
Recent genome-scale exome sequencing analysis of
276 colorectal tumors, DNA copy number, promoter
methylation and messenger RNA and microRNA expres-
sion conducted by the Cancer Genome Atlas project,tatus
Group 2B-2 (n = 11) P-value4
9/2 0.32
59.1 ± 9.9 0.44
(40–76, 59)







d t-test for continuous variables. P-values below 0.05 are in bold type.
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cancers exhibited at least one alteration of genes in-
volved in the Wnt pathway including LRP5, FZD10,
FAM123B, AXIN2, APC, CTNNB1 (β-catenin), TCF7L2,
FBXW7 and SOX7. Thus, Wnt signaling pathway seems
to play a critical role in colorectal carcinogenesis in gen-
eral, although the spectrum of alterations may vary de-
pending on the distinct oncogenic pathways.
AXIN was identified as a component of the complex
in Wnt signaling pathway to regulate the levels of β-
catenin along with the wild type of adenomatous polyp-
osis coli (APC) gene [47]. AXIN1 plays as a scaffold
protein on which the complex for phosphorylation of β-
catenin by glycogen synthase kinase-3β (GSK-3β) is as-
sembled [48]. AXIN2 / Conductin was identified as an
AXIN homolog, which also played a scaffold protein,
and was found mutated in a subset of colorectal cancers
[47,49]. AXIN1 appears to be a constitutive component
of β-catenin degradation complex for maintenance of
basal life activity while AXIN2 is considered to be an in-
ducible component that is upregulated in response to in-
creases in β-catenin levels and thus serves to limit the
duration and intensity of the Wnt signal [50,51]. AXIN2
has been only found expressed in colon tissues (Additional
file 1: Figure S3).
Epigenetic silencing of AXIN2 in MSI colon cancer
was reported in 2006 [52]. However, aberrant methyla-
tion of AXIN2 in SSA has not been previously reported.
In addition, we identified an apparent increase in methy-
lation alterations of AXIN2 from SSAs to MSI carcin-
omas, suggesting that its expression deregulation by
methylation associates with the serrated adenoma-MSI
cancer pathway.
The hierarchical tree identified three clusters accord-
ing to methylation profiles, MSI, SSAs epigenetically
close to MSI and SSAs far from MSI. The expression
levels of AXIN2 in these three groups associated with
the levels of methylation of AXIN2 in each group, re-
spectively (Figure 3). Our results suggest that expanding
of methylation in the promoter region of AXIN2 in SSAs
lead to the suppression of the AXIN2 gene expression
gradually, which contributes to a stepwise acquisition of
the epigenetic features seen in MSI colon cancer.
Koinuma et al. [52] reported that overexpression of
AXIN2, either by treatment with 5′-azacytidine or by
transfection with AXIN2 cDNA, resulted in rapid cell
death in a MSI CRC cell line, which supports the func-
tional significance of AXIN2 changes in methylation and
expression in our study. Dong et al. [24] reported pro-
gressive methylation of several genes during the serrated
pathway. In contrast with the epigenetic silencing of
AXIN2 in MSI colon cancer, up-regulation of AXIN2
mRNA was reported in MSS cancers. Indeed, in our
study, AXIN2 was frequently hypomethylated in MSScancers, suggesting that the epigenetic change of AXIN2
specifically associates with the MSI pathway for colon
cancer. The fact that down-regulation is not always ac-
companied by methylation (Figure 3) shows that add-
itional mechanisms may be at play to inactivate the
suppressor function of the AXIN2 protein. For instance,
frameshift mutations of AXIN2 in MSI colon cancers
may be one such additional mechanism [49,53,54].
The epigenetic influence on MSI manifestation is
shown by the hypermethylation and silencing of MLH1
[55]. High level of hypermethylation has been also asso-
ciated with MSI cancers [19,56], and also in SSAs
[9,13,15,16,24-26,57,58]. However, MLH1 methylation
was not detectable in SSAs in contrast with the common
presence observed in MSI cancers. This shows that the
epigenetic silencing of MLH1 is not involved in SSA de-
velopment where it must occur sometime during the ad-
enoma expansion. But silencing of MLH1 then appears
to drive the adenoma cells towards the carcinoma state
by the generation of many subsequent mutations. The
difference in age between the patients with SSAs and
MSI carcinomas also supports this suggestion, implying
a necessary additional step after SSA development for
the accumulation of oncogenic mutations responsible
for the carcinoma transition.
AXIN2 aberrant methylation appears to occur during
adenoma growth like MLH1 methylation. The assump-
tion here is that no methylation of MLH1 is found at the
SSA stage because once it occurs it may lead to the car-
cinoma transition in the absence of further clonal expan-
sion, since mutator genes do not alter the growth
properties of the cells. The association observed between
aberrant methylation and down-regulation with small
size SSAs without crypt branching could be interpreted
assuming that the occurrence of MLH1 methylation may
speed the transition to carcinoma in the absence of a
need for further expansion of the adenoma.
Conclusions
In conclusion, this study revealed that methylation aber-
rations likely play a role in the serrated adenoma-MSI
carcinoma sequence in colon cancer. Although the sam-
ples in this study are too limited to draw definitive con-
clusions in some genetic or epigenetic comparisons,
other differences were sufficiently large to reach statis-
tical significance. MLH1 silencing seem to occur in an
already developed serrated adenoma by the previous oc-
currence of somatic mutation in the BRAF oncogene.
Once the serrated adenoma has evolved, additional som-
atic alterations altering Wnt signaling, such as AXIN2
methylation or frameshift mutation, may contribute to
the adenoma’s further growth. Other genes besides
AXIN2, were identified that exhibit methylation profiles
shared between SSA and MSI CRC and would be
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interact with each other during the progression of colon
cancer of the serrated adenoma-MSI carcinoma sequence.
Nevertheless, when, contemporary with these somatic alter-
ations, aberrant methylation of the MLH1 gene occurs, this
appear to be the determinant event in those cases that
eventually progress to the carcinoma stage by providing the
cells with a strong mutator phenotype.
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